← Back to Search

18F-FAC PET Scan for Pancreatic Cancer

Q: Is this trial open to recruitment of participants?

<p>According to the information publicly available on clinicaltrials.gov, this medical trial is actively recruiting participants at the time of writing. The initial posting was made on November 18th 2021 and has since been updated as recently as 16th November 2022.</p>

Q: What is the approximate size of the current cohort involved in this investigation?

<p>Affirmative, the details available on clinicaltrials.gov declare that this medical research is currently accepting applicants. The trial was initiated on November 18th 2021 and has been modified most recently on November 16th 2022. This project necessitates 30 participants across a single site.</p>

Phase < 1

Recruiting

Led By Heiko Schoder, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with histologically-confirmed (confirmed at MSKCC) PDAC

Patients must be ≥ 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial will test whether a PET scan using 18F-FAC can show how much standard chemotherapy for pancreatic cancer may be taken up by the cancer.

Who is the study for?

This trial is for adults with confirmed pancreatic cancer (PDAC) who can undergo PET/CT scans. They must be in relatively good health, have a life expectancy of at least 3 months, and not be pregnant or breastfeeding. The study requires informed consent and the ability to have measurable disease on imaging scans.Check my eligibility

What is being tested?

The trial is testing if an experimental PET scan using a tracer called 18F-FAC can predict how well standard chemotherapy will work in treating PDAC by measuring its uptake in the tumor before treatment begins.See study design

What are the potential side effects?

Since this trial involves only diagnostic imaging with a PET scan, side effects are minimal but may include discomfort from lying still during the procedure and exposure to low levels of radiation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My pancreatic cancer diagnosis was confirmed through tissue analysis.

Select...

I am 18 years old or older.

Select...

I am able to care for myself and perform normal activities with minimal assistance.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Tumor drug uptake within PDAC tumors prior at pre-treatment baseline

Secondary outcome measures

changes in [18F]-FAC drug uptake during or following SOC chemo- and/or radiation therapy.

Side effects data

From 2018 Phase 3 trial • 156 Patients • NCT02516046

agitation

headache

dizziness postural

acute kidney injury

malignant neoplasm

myocardial infarction

vertigo

diarrhoea

nausea

injection site bruising

fall

procedural vomiting

hypomagnesaemia

myopathy

hypoxic-ischaemic encephalopathy

tremor

mental disorder

restlessness

Cardiac failure congestive

100%

80%

60%

40%

20%

Study treatment Arm

Safety Analysis Population

Trial Design

1Treatment groups

Experimental Treatment

Group I: Participants with pancreatic ductal adenocarcinoma (PDAC)Experimental Treatment1 Intervention

Participants will have histologically-confirmed pancreatic ductal adenocarcinoma (PDAC). The experimental design of this study is to perform a single [18F]-FAC PET scan prior to the administration of chemotherapy with an optional second [18F]-FAC PET scan procedure during SOC treatment to observe changes in tumor uptake and biodistribution. Patients will be offered a second [18F]-FAC PET scan procedure during their SOC treatment. This second scan will be optional.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

PET Scan

2006

Completed Phase 3

~590

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,936 Previous Clinical Trials

588,851 Total Patients Enrolled

Heiko Schoder, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

6 Previous Clinical Trials

685 Total Patients Enrolled

Media Library

Pancreatic Cancer Research Study Groups: Participants with pancreatic ductal adenocarcinoma (PDAC)

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial open to recruitment of participants?

"According to the information publicly available on clinicaltrials.gov, this medical trial is actively recruiting participants at the time of writing. The initial posting was made on November 18th 2021 and has since been updated as recently as 16th November 2022."

Answered by AI

What is the approximate size of the current cohort involved in this investigation?

"Affirmative, the details available on clinicaltrials.gov declare that this medical research is currently accepting applicants. The trial was initiated on November 18th 2021 and has been modified most recently on November 16th 2022. This project necessitates 30 participants across a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer

2021. "Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05141643.